Atom Therapeutics Co. Ltd., a clinical stage biotechnology company founded in 2012, is developing best-in-class small molecule drugs for treatment of metabolic, inflammatory and cardiovascular diseases.
Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout and hyperuricemia. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs on the market.
Another small molecule, ABP-745 for acute gout, has demonstrated safety and efficacy in completed Phase 1 clinical trials in the US. ABP-745 is in Phase 2 clinical trials for acute gout and preparations are underway for Phase 2 clinical trials in other indications.